期刊文献+

艾塞那肽治疗2型糖尿病的疗效观察 被引量:1

下载PDF
导出
摘要 目的:评价艾塞那肽治疗2型糖尿病的疗效。方法:糖尿病住院患者20例(治疗组)给予二甲双胍联合艾塞那肽治疗,随机选择与治疗组同时期住院,年龄、病程、体重指数(BMI)、空腹血糖(FBG)和餐后2小时血糖(PG2h)、糖化血红蛋白(HbA1c)无显著差异的患者作为对照组,给予二甲双胍联合格列美脲治疗,比较治疗前后两组患者FBG、PG2h、HbA1c、BMI、低血糖发生次数。结果:两组治疗16周后FBG、PG2h、HbA1c均较治疗前明显下降(P<0.05),但两组之间差异无统计学意义(P>0.05)。对照组治疗前后的BMI差异无统计学意义(P>0.05),治疗组治疗16周后的BMI明显小于治疗前(P>0.05),治疗组发生症状性低血糖及夜间低血糖次数都明显少于对照组(P<0.01)。结论:艾塞那肽可有效控制血糖,并且能明显降低BMI和低血糖发生次数。
出处 《吉林医学》 CAS 2012年第34期7476-7477,共2页 Jilin Medical Journal
  • 相关文献

参考文献10

  • 1Arakawa M,Ebato C,Mita T,et al.Effects of exendin-4on glucose Tolerance,insulin secertion,and beta-cell proliferation depend on treatment dose,treatment duration and meal contents[J].Biochem Biophys Res commun,2009,390(3):809.
  • 2Eng J,Kleinman WA,Singh L,et al.Isolation and charac-terization of exendin-4,an exendin-3analogue,from Heloderma suspectum venom.Further evidengce foran Exendin receptor on dispersed acini from guinea pig pancreas[J].J Biol Chem,1992,267(11):7402.
  • 3骆天红,郑以漫.胰升糖素样肽1对胰岛β细胞作用的研究进展[J].中华内分泌代谢杂志,2008,24(6). 被引量:38
  • 4World Health Organization.Definition,diagnosis and classi-fications of diabetes mellitus and its compliacations.Report of a WHO consultation,Part1:diagnosis and classification of diabetes mellitus[S].Geneva:WHO,1999.
  • 5中国医学会糖尿病学分会.中国2型糖尿病防治指南(附录6常规体质指标)[S].2007.
  • 6随华,耿秀琴,刘纯,王林栋.应用磺脲类药物和二甲双胍治疗2型糖尿病失效后补充第3种降糖药的选择[J].中国药房,2010,21(2):152-154. 被引量:18
  • 7Hemndez-Daz S,Adami HO.Diabetes therapy and cancer risk:causal effects and other plausible explanations[J].Diabeto-logia,2010,53(5):802.
  • 8Fehse F,Trautmann M,HoIst JJ,et aI.Exenatide augments first-and second-phase insuIin secretion in response to intrave-nous gIucose insubjects with type2diabetes[J].J CIin Endocrinol Metab,2005,90(11):5991.
  • 9杨红旺,刘洋,袁勃,孟雁.GLP-1的生理作用与临床[J].中国糖尿病杂志,2009,17(1):78-80. 被引量:26
  • 10单忠艳.GLP-1类似物在糖尿病治疗中的作用[J].药品评价,2009(12):500-501. 被引量:7

二级参考文献44

  • 1陈岷,张伶俐,孙世明,李获.糖尿病药物治疗新进展[J].中国药房,2006,17(19):1508-1509. 被引量:11
  • 2Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
  • 3Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
  • 4Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
  • 5Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
  • 6Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
  • 7Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes, 2006,55 : 1190-1196.
  • 8De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
  • 9MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.
  • 10Dyachok O, Isakov Y, Sagetorp J, et al. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting β-cells. Nature, 2006,439 : 349- 352.

共引文献80

同被引文献5

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部